This article is more than 5 years old. Information may no longer be current.

Kala posts quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Kala Pharmaceuticals reported a net loss of $15.6 million, or $0.63 per share, for the third quarter of 2018 compared with a net loss of $10.2 million, or $0.56 per share, a year ago, according to a press release.

Research and development costs stayed at $7 million year-over-year, whereas general and administrative costs increased from $2.5 million in 2017’s third quarter to $8.5 million in 2018. The company attributed the increase to commercial-related costs in anticipation of the launch of Inveltys (loteprednol etabonate ophthalmic suspension 1%) in early 2019.

Kala had $74.9 million in cash as of Sept. 30.